Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02613897 · ClinicalTrials.gov registry record · NA
ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study
A NA study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT02613897 is a NA study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 56 participants.
The verdict
NCT02613897, a NA study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a 16-week, single center, randomized, double-blind, active-controlled, parallel-group, Phase 3b efficacy and safety study of simultaneous administration of saxagliptin 5 mg plus dapagliflozin 10 mg once daily (QD) compared with dapagliflozin plus placebo for saxagliptin, and placebo for saxagliptin plus placebo for dapagliflozin in patients with Type 2 diabetes who have inadequate glycemic control on metformin or metformin/sulfonylurea.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
- DRUG Saxagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2016-01 |
| Est. Completion | 2018-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02613897
The ClinicalTrials.gov registry entry for NCT02613897 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02613897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02613897 about?
NCT02613897 is a clinical study titled "ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study". This is a 16-week, single center, randomized, double-blind, active-controlled, parallel-group, Phase 3b efficacy and safety study of simultaneous administration of saxagliptin 5 mg plus dapagliflozin 10 mg once daily (QD) compared with dapagliflozin plus placebo for saxagliptin, and placebo for saxa...
What is the current status of trial NCT02613897?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2016-01. Estimated completion is 2018-06-30.
What interventions are being tested in trial NCT02613897?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG), Saxagliptin (DRUG).
Who is sponsoring clinical trial NCT02613897?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.